Skip to main content
. 2012 Aug 3;7(8):e42701. doi: 10.1371/journal.pone.0042701

Table 12. Methodological quality of RCTs evaluating bevacizumab for indirect comparison.

Study Comparability of groups Adequate blinding Definition of expected AE Definition of method used to collect AE data Transparency of patient flow Validity safety
Sacu et al. 2009 [26] in part open label no no yes low
Costagliola et al. 2010 [27] not specified not specified no no unclear low
ABC Trial 2010 [28] in part double blind in part in part yes moderate

AE: Adverse effects.